SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.240-1.2%Dec 22 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
mattstat
To: RoadyHD who wrote (12541)12/14/2019 9:59:03 PM
From: HardToFind1 Recommendation  Read Replies (1) of 12873
 
NNVC's licensing deals with TheraCour would be acceptable and reasonably attractive if NNVC were a BP (hence the supposed "fair" opinions) with lots of cash and capital and a distribution channel.
I would argue the 15% royalty rate might be fair IF...and it's a big IF...if TheraCour had taken all of the development risk through Phase II. As we're all well aware, NNVC has risked and lost $100 Mn at the hands of Diwan, largely on licensed drug development that has so far proven worthless. And yet, having risked little to nothing until he spent all of NNVC's money, Diwan thinks he deserves $9 Mn (plus what he has recently lent the company), in addition to a 15% royalty.

Given the circumstances, I disagree about the acceptability and attractiveness, even for a Big Pharma. I think they would demand better terms from Diwan, which is why, from the beginning, Diwan pulled the deceptive shenanigans that caused Yidam to sue. If it were fair, he could have dealt honestly with shareholders from the beginning. He didn't do that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News